• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by China Pharma Holdings Inc. (Amendment)

    12/5/22 3:01:51 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPHI alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
    China Pharma Holdings, Inc. 

    (Name of Issuer)
     
    Common stock, $0.001 par value

    (Title of Class of Securities)
     
    16941T104

    (CUSIP Number)
     
    December 05, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  16941T104      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Streeterville Capital LLC
    85-2954598
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Utah
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     5,159,088
       
    6 SHARED VOTING POWER
      
     
       
    7 SOLE DISPOSITIVE POWER
      
     5,159,088
       
    8 SHARED DISPOSITIVE POWER
      
     
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     5,159,088
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     9.99*%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     OO
     

    FOOTNOTES
      
     * Reporting Person Streeterville Capital LLC (“Streeterville”) has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer’s ordinary shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's ordinary shares beneficially owned by Streeterville as of the date of this filing was 5,159,088 shares, which is 9.99% of the 51,642,530 shares outstanding on November 9, 2022, (as reported in the Issuer's 10-Q filed on November 14, 2022).
     
     

     
     
    CUSIP No.  16941T104      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Streeterville Management LLC
    85-3223919
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Utah
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     5,159,088
       
    6 SHARED VOTING POWER
      
     
       
    7 SOLE DISPOSITIVE POWER
      
     5,159,088
       
    8 SHARED DISPOSITIVE POWER
      
     
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     5,159,088
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     9.99*%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     OO
     

    FOOTNOTES
      
     * Reporting person Streeterville Management LLC is the Manager of reporting person Streeterville. Streeterville has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer’s ordinary shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's ordinary shares beneficially owned by Streeterville as of the date of this filing was 5,159,088 shares, which is 9.99% of the 51,642,530 shares outstanding on November 9, 2022, (as reported in the Issuer's 10-Q filed on November 14, 2022).
     
     

     
     
    CUSIP No.  16941T104      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     John M. Fife
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     United States of America
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     5,159,088
       
    6 SHARED VOTING POWER
      
     
       
    7 SOLE DISPOSITIVE POWER
      
     5,159,088
       
    8 SHARED DISPOSITIVE POWER
      
     
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     5,159,088
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     9.99*%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IN
     

    FOOTNOTES
      
     * John M. Fife is the sole member of Streeterville Management LLC, which is the Manager of reporting person Streeterville. Streeterville has rights under a Convertible Promissory Note to own an aggregate number of shares of the Issuer’s ordinary shares which, except for a contractual cap on the amount of outstanding shares that Streeterville may own, would exceed such cap. Streeterville's current ownership cap is 9.99%. Thus, the number of shares of the Issuer's ordinary shares beneficially owned by Streeterville as of the date of this filing was 5,159,088 shares, which is 9.99% of the 51,642,530 shares outstanding on November 9, 2022, (as reported in the Issuer's 10-Q filed on November 14, 2022).
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    China Pharma Holdings, Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    2nd Floor
    No. 17 Jinpan Rd.
    Hainan Province 570216
    China

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    This report is filed by Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife with respect to the shares of common stock of the Issuer that are directly beneficially owned by Streeterville Capital LLC and indirectly beneficially owned by the other reporting and filing persons.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    303 E Wacker Drive, Suite 1040
    Chicago, IL 60601

     
    (c)
    Citizenship
     
     
    Streeterville Capital LLC is a Utah limited liability company.
    Streeterville Management LLC is a Utah limited liability company.
    John M. Fife is a United States citizen.

     
    (d)
    Title of Class of Securities
     
     
    Common stock, $0.001 par value per share

     
    (e)
    CUSIP Number
     
     
    16941T104

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 5,159,088

     
    (b)
    Percent of class: 9.99%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 5,159,088

     
    (ii)
    Shared power to vote or to direct the vote: 0

     
    (iii)
    Sole power to dispose or to direct the disposition of: 5,159,088

     
    (iv)
    Shared power to dispose or to direct the disposition of: 0

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     Streeterville Capital LLC
     
        
    Date: December 05, 2022
    By:
    /s/  John M. Fife 
       Name: John M. Fife 
       Title:  President 
        
     
     
     
     Streeterville Management LLC
     
        
    Date: December 05, 2022
    By:
    /s/  John M. Fife 
       Name: John M. Fife 
       Title:  Member 
        
     
     
     
     John M. Fife
     
        
    Date: December 05, 2022
    By:
    /s/  John M. Fife 
       Name: John M. Fife 
       
        
     
    Footnotes:

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $CPHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CPHI
    SEC Filings

    See more
    • SEC Form 10-Q filed by China Pharma Holdings Inc.

      10-Q - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

      5/14/25 4:20:46 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China Pharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

      4/4/25 4:05:20 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by China Pharma Holdings Inc.

      10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

      3/31/25 4:20:27 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by China Pharma Holdings Inc.

      SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)

      1/26/24 5:04:49 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by China Pharma Holdings Inc. (Amendment)

      SC 13G/A - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)

      1/12/24 2:42:50 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by China Pharma Holdings Inc.

      SC 13G - CHINA PHARMA HOLDINGS, INC. (0001106644) (Subject)

      3/9/23 4:06:22 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Liu Tao (Chengdu) claimed ownership of 15,000,000 shares (SEC Form 3)

      3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

      1/26/24 5:04:12 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Li Zhilin was granted 13,757,063 shares, increasing direct ownership by 996% to 15,138,063 units (SEC Form 4)

      4 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

      10/19/23 4:06:09 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Deng Ke claimed ownership of 1,552,230 shares

      3 - CHINA PHARMA HOLDINGS, INC. (0001106644) (Issuer)

      3/9/23 4:05:23 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPHI
    Financials

    Live finance-specific insights

    See more

    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project

      HAIKOU, China, Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. This device has a patentEpidemiological research shows that the incidence rate of DED is about 25% to 30%, and the incidence rate of people over 65-year-old is 75% in ChinaAccording to the Research Report on the Market Status of the Global Dry Eye Disease Drug Industry in 2022(1), the market size of DED drugs in China in 2021 was approximately RMB3.85 billion (approximately US$0.5

      12/5/22 8:00:00 AM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

      HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE:CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Tuesday, April 15, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T 401. The reverse stock split at a ratio ranges between 1:10 and 1:20 was authorized by the Company's Board of Directors (the "Board") through unanimous written consent on October 22, 2024 and adopted by

      4/4/25 4:05:00 PM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville

      HAIKOU, China, Dec. 18, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced successful completion of all redemptions under its Convertible Promissory Note agreement (the "Convertible Promissory Note") with Streeterville Capital, LLC as of December 11, 2024. This marks a significant step in strengthening the company's financial position and reflects its commitment to sound fiscal management. The Convertible Promissory Note was originally issued on November 17, 2021, with a principal amount of $5,250,000. Following a

      12/18/24 8:30:00 AM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China Pharma Announces the Entry of "At-The-Market" Equity Offering

      HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing"). The shares will be offered pursuant to a certain Securities Purchase Agreement (the "SPA") the Company entered into with certain investor (the "Investor") on December 12, 2024. Pursuant to the SPA, the Investor agrees t

      12/13/24 8:00:00 AM ET
      $CPHI
      Biotechnology: Pharmaceutical Preparations
      Health Care